Siok Ping Yeo

This inventor holds 1 USPTO granted patent. Top assignee: Agency for Science, Technology and Research. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Siok Ping Yeo. Retrieved from https://idiyas.com/inventor/siok-ping-yeo-ezw1b8sj

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Siok Ping Yeo: Innovator in Antibody Development

Introduction

Siok Ping Yeo is a notable inventor recognized for his contributions to the field of biotechnology. He is particularly known for his work on anti-PD-L1 antibodies, which play a significant role in cancer immunotherapy. His innovative approach has the potential to impact treatment options for patients.

Latest Patents

Siok Ping Yeo holds a patent for "ANTI-PD-L1 ANTIBODIES." This patent represents a significant advancement in the development of therapeutic agents aimed at enhancing the immune response against cancer cells. His work in this area showcases his commitment to improving healthcare outcomes.

Career Highlights

Siok Ping Yeo is affiliated with the Agency for Science, Technology and Research, where he has been instrumental in various research initiatives. His career is marked by a dedication to scientific excellence and innovation in the biotechnology sector.

Collaborations

Throughout his career, Siok Ping Yeo has collaborated with esteemed colleagues, including Cheng-I Wang and Hsueh Ling Janice Oh. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Siok Ping Yeo's contributions to the field of biotechnology, particularly in the development of anti-PD-L1 antibodies, highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and immunotherapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…